Ani Pharmaceuticals (ANIP) Free Cash Flow Growth (3y) (2013 - 2026)
Powered by 
Analysis
Ani Pharmaceuticals (ANIP) Free Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 14.41% |
| 2 | Viatris | 19.20 Bn | 18.31 Bn | 1.46 Bn | -10.40% |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.73 Bn | 396.53 Mn | -47.39% |
| 4 | Amneal Pharmaceuticals | 5.49 Bn | 5.36 Bn | 334.51 Mn | -30.54% |
| 5 | Bausch Health Companies | 2.31 Bn | 475.75 Mn | 2.10 Bn | 49.35% |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | - |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 43.55% |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 711.29 Mn | 93.47 Mn | -2.33% |
| 9 | Fennec Pharmaceuticals | 396.40 Mn | 355.15 Mn | 17.15 Mn | - |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 43.55% |
| Mar 31, 2026 | 39.96% |
| Dec 31, 2025 | 80.32% |
| Sep 30, 2025 | 220.30% |
| Jun 30, 2025 | 96.67% |
| Mar 31, 2025 | 52.64% |
| Dec 31, 2024 | 45.40% |
| Sep 30, 2024 | 48.62% |
| Jun 30, 2024 | 174.85% |
| Mar 31, 2024 | -11.83% |
| Dec 31, 2023 | 95.14% |
| Sep 30, 2023 | 122.51% |
| Jun 30, 2023 | -3.48% |
| Mar 31, 2023 | 381.38% |
| Dec 31, 2022 | -64.26% |
| Sep 30, 2022 | -61.52% |
| Jun 30, 2022 | -82.89% |
| Mar 31, 2022 | -54.24% |
| Dec 31, 2021 | -35.33% |
| Sep 30, 2021 | -41.94% |